Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference

Neuropsychopharmacology. 2007 Jan;32(1):117-26. doi: 10.1038/sj.npp.1301034. Epub 2006 Feb 8.

Abstract

Endocannabinoid signaling has recently been implicated in ethanol-seeking behavior. We analyzed the expression of endocannabinoid-related genes in key brain regions of reward and dependence, and compared them between the alcohol-preferring AA (Alko Alcohol) and nonpreferring ANA (Alko Non-Alcohol) rat lines. A decreased expression of fatty acid amidohydrolase (FAAH), the main endocannabinoid-degrading enzyme, was found in prefrontal cortex (PFC) of AA rats, and was accompanied by decreased enzyme activity in this region. Binding of the endocannabinoid-cannabinoid 1 (CB1) receptor ligand (3)[H]SR141716A, and [35S]GTPgammaS incorporation stimulated by the CB1 agonist WIN 55,212-2 were downregulated in the same area. Together, this suggests an overactive endocannabinoid transmission in the PFC of AA animals, and a compensatory downregulation of CB1 signaling. The functional role of impaired FAAH function for alcohol self-administration was validated in two independent ways. The CB1 antagonist SR141716A potently and dose-dependently suppressed self-administration in AA rats when given systemically, or locally into the PFC, but not in the striatum. Conversely, intra-PFC injections of the competitive FAAH inhibitor URB597 increased ethanol self-administration in nonselected Wistar rats. These results show for the first time that impaired FAAH function may confer a phenotype of high voluntary alcohol intake, and point to a FAAH both as a potential susceptibility factor and a therapeutic target.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Alcohol Drinking / genetics*
  • Amidohydrolases / genetics
  • Amidohydrolases / metabolism
  • Analgesics / pharmacology
  • Animals
  • Behavior, Animal / drug effects
  • Benzamides / pharmacology
  • Benzoxazines
  • Brain Chemistry / drug effects
  • Brain Chemistry / genetics
  • Cannabinoid Receptor Modulators / metabolism*
  • Carbamates / pharmacology
  • Central Nervous System Depressants / administration & dosage
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Endocannabinoids*
  • Ethanol / administration & dosage
  • Gene Expression / drug effects
  • Gene Expression / physiology*
  • Guanosine 5'-O-(3-Thiotriphosphate) / pharmacokinetics
  • In Situ Hybridization / methods
  • Male
  • Morpholines / pharmacology
  • Naphthalenes / pharmacology
  • Piperidines / pharmacokinetics
  • Prefrontal Cortex / drug effects
  • Prefrontal Cortex / metabolism*
  • Pyrazoles / pharmacokinetics
  • RNA, Messenger / metabolism
  • Rats
  • Receptor, Cannabinoid, CB1 / genetics
  • Receptor, Cannabinoid, CB1 / metabolism*
  • Reverse Transcriptase Polymerase Chain Reaction / methods
  • Rimonabant
  • Self Administration / methods

Substances

  • Analgesics
  • Benzamides
  • Benzoxazines
  • Cannabinoid Receptor Modulators
  • Carbamates
  • Central Nervous System Depressants
  • Endocannabinoids
  • Morpholines
  • Naphthalenes
  • Piperidines
  • Pyrazoles
  • RNA, Messenger
  • Receptor, Cannabinoid, CB1
  • cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester
  • Guanosine 5'-O-(3-Thiotriphosphate)
  • Ethanol
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Amidohydrolases
  • fatty-acid amide hydrolase
  • Rimonabant